Bonus Biogroup Market Cap ($51.35 Million)
Market Cap & Net Worth: Bonus Biogroup (BONS)
Bonus Biogroup market cap. Bonus Biogroup (TA:BONS) has a market capitalization of $51.35 Million (ILA19.15 Billion) as of November 5, 2026. Listed on the TA stock exchange, this Israel-based company holds position #21613 globally and #288 in its home market, demonstrating a -9.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bonus Biogroup's stock price ILA16.40 by its total outstanding shares 1167925311 (1.17 Billion). Also see BONS cash flow conversion for how efficiently the company converts equity into cash flow.
Bonus Biogroup Market Cap History (2015–2026)
Bonus Biogroup market cap history from 2015 to 2026. Data shows change from $211.04 Million to $51.35 Million (-8.73% CAGR). Check BONS stock price and chart for real-time trading data and today's change.
Bonus Biogroup Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bonus Biogroup's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BONS net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BONS by Market Capitalization
Companies near Bonus Biogroup in the global market cap rankings as of November 5, 2026. Also see Bonus Biogroup (BONS) total assets for a full breakdown of the balance sheet.
Key companies related to Bonus Biogroup by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Bonus Biogroup (2015–2026)
Market capitalization of Bonus Biogroup from 2015 to today. Between 2015 and today, Bonus Biogroup's market cap moved from $211.04 Million to $ 51.35 Million, with a yearly change of -8.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA51.35 Million | -33.87% |
| 2025 | ILA77.65 Million | +110.17% |
| 2024 | ILA36.95 Million | -29.76% |
| 2023 | ILA52.60 Million | -12.95% |
| 2022 | ILA60.43 Million | -84.68% |
| 2021 | ILA394.53 Million | +162.50% |
| 2020 | ILA150.30 Million | +8.60% |
| 2019 | ILA138.40 Million | +19.14% |
| 2018 | ILA116.17 Million | -32.55% |
| 2017 | ILA172.21 Million | -1.96% |
| 2016 | ILA175.66 Million | -16.77% |
| 2015 | ILA211.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Bonus Biogroup was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.35 Million USD |
| MoneyControl | $51.35 Million USD |
| MarketWatch | $51.35 Million USD |
| marketcap.company | $51.35 Million USD |
| Reuters | $51.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bonus Biogroup
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more